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Drug sensitivity testing on patient-derived sarcoma cells
predicts patient response to treatment and identifies c-Sarc
inhibitors as active drugs for translocation sarcomas
Bertha A. Brodin1, Krister Wennerberg2,3, Elisabet Lidbrink4, Otte Brosjö5, Swapnil Potdar2, Jennifer N. Wilson1, Limin Ma1,
Lotte N. Moens7, Asle Hesla5, Edvin Porovic1, Edvin Bernhardsson1, Antroula Papakonstantinou4,8, Henrik Bauer5,
Panagiotis Tsagkozis5,8, Karin von Sivers9, Johan Wejde6, Päivi Östling8, Olli Kallioniemi8 and Christina Linder Stragliotto4
BACKGROUND: Heterogeneity and low incidence comprise the biggest challenge in sarcoma diagnosis and treatment.
Chemotherapy, although efficient for some sarcoma subtypes, generally results in poor clinical responses and is mostly
recommended for advanced disease. Specific genomic aberrations have been identified in some sarcoma subtypes but few of them
can be targeted with approved drugs.
METHODS: We cultured and characterised patient-derived sarcoma cells and evaluated their sensitivity to 525 anti-cancer agents
including both approved and non-approved drugs. In total, 14 sarcomas and 5 healthy mesenchymal primary cell cultures were
studied. The sarcoma biopsies and derived cells were characterised by gene panel sequencing, cancer driver gene expression and
by detecting specific fusion oncoproteins in situ in sarcomas with translocations.
RESULTS: Soft tissue sarcoma cultures were established from patient biopsies with a success rate of 58%. The genomic profile and
drug sensitivity testing on these samples helped to identify targeted inhibitors active on sarcomas. The cSrc inhibitor Dasatinib was
identified as an active drug in sarcomas carrying chromosomal translocations. The drug sensitivity of the patient sarcoma cells
ex vivo correlated with the response to the former treatment of the patient.
CONCLUSIONS: Our results show that patient-derived sarcoma cells cultured in vitro are relevant and practical models for
genotypic and phenotypic screens aiming to identify efficient drugs to treat sarcoma patients with poor treatment options.
British Journal of Cancer (2019) 120:435–443; https://doi.org/10.1038/s41416-018-0359-4
INTRODUCTION
Sarcomas are aggressive tumours originating from connective
tissues with an incidence of 1% of all adult cancers. They comprise
approximately 130 distinct histological subtypes according to the
World Health Organization (WHO) classification of bone and soft
tissue tumours.1 Surgery is the cornerstone for the treatment of
sarcoma. In spite the fact that some sarcoma subtypes such as
osteosarcomas and Ewing sarcomas are sensitive to cytostatic
drugs, conventional chemotherapy has limited benefit for most
sarcoma subtypes and is usually recommended for advanced
disease.2–4 Heterogeneity and low incidence have been a great
challenge for sarcoma diagnosis, treatment, drug development
and clinical trials.
Genetically, sarcomas divide into two groups: those with
complex genomes comprising of approximately 60% of all cases
and those with characteristic genetic alterations, such as
chromosomal translocations, that are often drivers of sarcoma-
genesis. This group accounts for 40% of the sarcoma cases.5
New generation sequencing technology has been used to
elucidate the genomes and transcriptomes of several human
cancers, including sarcomas.6 It has shown that cancer cells
gradually acquire genetic aberrations such as mutations, changes
in gene copy numbers, and gene fusions, but only a few hundred
of these alterations are essential for tumourigenesis or for cancer
cell survival.6,7
Sarcomas with high rate of mutations include subtypes such as
leiomyosarcoma,8 osteosarcoma,9 undifferentiated pleomorphic
sarcoma9 and dedifferentiated liposarcoma.10 Sarcomas with
chromosomal translocations express specific fusion genes that
are drivers of sarcomagenesis but seldom acquire secondary
genetic aberrations.10,11 This has been confirmed in a compre-
hensive study with 206 sarcomas representing six different
subtypes.12 The most common genetic aberrations found in this
study were amplifications of the MDM2, CDK4, HMG2 genes, and
deletions in the RB1, TP53, PTEN,CDKN2A and NF1 genes.
Sarcomas acquire less gene mutations compared to tumours of
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epithelial origin. These are most common in the TP53, RB and
ATRX genes.11,12
This information has been useful to identify genetic aberrations
in tumours that can be targeted by newly developed drugs.9,10,13
However, to date, only a few of these alterations are matched to
approved drugs and less than 5% of the information generated is
used to guide patient treatment. The therapeutic efficacy of large-
scale genetic profiling on patient tumours is still challenging.
Phenotypic or functional screening can be an alternative to
overcome this gap. It refers to the identification of molecules with
particular biological effects using cell, tissue-based assays or
animal models. Phenotypic screening using cancer models such as
patient-derived tumour cells (PDCs), organoids and patient-
derived xenografts (PDX) is an efficient approach to identify
treatments or new therapeutic indications for approved drugs.14,15
The use of PDCs and PDXs in drug screens is gaining considerable
interest since these models represent a closer surrogate to the
patient tumour. Furthermore, the use of approved drugs for other
treatment indications can be accelerated since the preclinical and
safety studies in humans have already been performed.
In the present study, we cultured patient-derived sarcoma cell
and characterised these cells and the biopsy of origin by analysing
gene mutations, cancer driver gene and fusion protein expression.
We further determined the sensitivity of the patient-derived
sarcoma cells to a library of approved and investigational drugs to
evaluate if this approach can be useful to identify targeted inhibitors
with potential therapeutic effects for individual sarcoma patients.
MATERIAL AND METHODS
Establishment of sarcoma patient-derived cells (PDC)
Patient-derived cells were dissociated from solid biopsies through
mechanic grinding followed by enzymatic digestion using a 0.1%
collagenase mixture for 1−2 h at 37 °C under gentle agitation. The
cell mixture was then passed through a 100 μm mesh, and the
collagenase solution was replaced by fresh culturing medium.
Most sarcoma cells were grown in Dulbecco’s modified Eagle’s
medium/Ham’s nutrient mixture F12 (DMEM/F12) supplemented
with 15% fetal bovine serum (FBS), non-essential amino acids,
penicillin and streptomycin. Angiosarcoma cells were cultured in
endothelial cell media containing vascular endothelial growth
factor (VEGF), insulin growth factor (IGF) and basic fibroblast
growth factor (FGF). Muscle cells were grown in skeletal muscle
cell media containing 5% fetal calf serum, basic FGF, insulin, and
dexamethasone (Promocell, Germany).
Ewing’s sarcoma (ES), alveolar rhabdomyosarcoma (aRMS) and
angiosarcoma samples were obtained by fine needle aspiration
(FNA) from palpable tumours. The content of tumour cells in the
FNA biopsy was assessed on site by microscopic evaluation of
Grunewald−Giemsa-stained FNA smears prior to in vitro
cultivation.
Logarithmic growing patient-derived cells (PDC) were estab-
lished within a range from 2 days to 18 weeks depending on the
biopsy size, cell viability and histological subtype.
Proximity ligation assay (PLA)
Primary cells were cultured in chamber slides for 24 h; thereafter
the medium was removed, and the cells were washed twice with
phospate buffered saline (PBS) and fixed for 15 min in 4%
paraformaldehyde, following permeabilisation with 0.1% Tri-
tonX100 for 15min. The PLA was performed according to the
in situ Fluorescence PLA protocol (Sigma-Aldrich). For detection of
fusion proteins, we used two antibodies raised in different species,
one recognising the N-terminus and the second recognising the
C-terminus of each chimeric protein. Species-specific antibodies
conjugated with DNA oligonucleotides were then used to
recognise the primary antibody. These DNA probes can be ligated
to form a circular probe only in the case that the two antibodies
are in the proximity. The DNA probe is subsequently amplified
using DNA polymerase and a fluorescent-labelled deoxynucleo-
tide in the amplification reaction allowing the visualisation of the
fusion protein in the UV-light range using a confocal microscope.
Cancer driver gene expression
RNA was isolated using AllPrep (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions and the quality of the RNA was
evaluated using a bioanalyser (Agilent, Sta Clara CA, USA). The
expression of 180 cancer driver genes (Supplementary table 4) was
performed using quantitative RT-PCR arrays (RealTimePrimers, Elkin
Park PA, USA) and AzuraQuantTM Green Fast qPCR Mix green master
mix (Azura Genomics, Rayham, MA USA). Gene expression analysis
was calculated using the Livak method, in which the ΔCT values
were calculated by normalising values for each gene to the
housekeeping genes, ΔΔCT was then calculated by normalising
the ΔCT values of either biopsy of patient-derived cells to that of the
normal muscle cells and used to determine the fold change (2−ΔΔCT).
Log2 (fold change) values were then plotted in a HeatMap using the
GENE-E software (Broad Institute).
Drug sensitivity and resistance testing (DSRT)
We used the drug sensitivity and resistance testing (DSRT)
developed at the Institute for Molecular Medicine Finland
(FIMM).16–19 The FIMM library is composed of 525 agents of which,
approximately 40% are drugs approved for treatment of different
human cancers and the remaining 60% are being investigated in
clinical trials. In this system, drug activity is calculated taking into
consideration the response curve and the IC50 for each drug and it
is expressed as drug sensitivity score (DSS).18
The compounds were dispensed in 384-well plates (Corning,
Tewksbury, MA, USA) at five different concentrations covering a
range between 1 and 10,000 nM using acoustic liquid handling
(Echo 550, Labcyte Inc, Sunnyvale, CA, USA).
Early passaged (passages 2−5) PDC growing as monolayers
were collected by tripsinisation. Twenty-five microliters of single-
cell suspensions containing 500–2000 cells were dispensed to
each well using a Multidrop Combi Reagent Dispenser (Thermo
Fisher Scientific, Maltham MA, USA). Plates were subsequently
centrifuged, put on an orbital shaker for 10min followed by
additional 10 min incubation at room temperature to allow the
cells to plate to the bottom.
The plates were incubated for 72 h at 37 °C, 5% CO2, and a
humidified environment. Cell viability was assessed by determin-
ing the total adenosine tri-phosphate (ATP) levels in living cells
using CellTiter-Glo (CTG) luminescent cell viability assay (Promega,
Madison, WI, USA). Luminescence was measured using a multi-
mode multiplate reader (Tecan F-Plex, Switzerland).
The selective drug sensitivity score (sDSS) was calculated by
subtracting the DSS of normal cell controls (healthy bone marrow
mononuclear cells or normal mesenchymal primary cells) from the
DSS of sarcoma cells.
Target enrichment and next-generation sequencing
Target enrichment was performed with the HaloPlex target
enrichment system (Agilent Technologies), according to the
manufacturer’s instructions. A custom gene panel was designed,
covering the coding regions of the 16 target genes listed in
Supplementary Table 1. The target genes were captured by 6063
probes, covering a total region of approximately 76 kb. The quality
and molarity of the sequencing libraries was assessed on a 2200
TapeStation instrument using a D1000 Screen tape (Agilent
Technologies). The enriched and barcoded targets were then
sequenced on a MiniSeq or NextSeq instrument (Illumina).
Data analysis
Illumina sequencing adaptors were removed by cutAdapt version
1.8.0 20 and the trimmed reads were subsequently aligned to the
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reference genome (hg19, March 2009 assembly) using BWA mem
version 0.7.12,21 allowing for a maximum of 5% mismatches in a
read. Single-nucleotide variation detection was performed using
SNPmania version 0.0.7 (Department of Immunology, Genetics
and Pathology, Uppsala University, Uppsala, Sweden) (Ljungström
et al, unpublished data, available on request). Insertion and
deletion detection was performed using Pindel version 0.2.5a8
with parameters -x 2, allowing the detection of indels up to 512
bp, and -B 100 allowing the detection of structural variants of size
~100 bp. Only positions having a read depth ≥ 30 and variant
allele frequency > 1% were considered. The variants were further
filtered to remove all synonymous mutations, as well as variants
having a frequency > 1% in the 1000Genome project20,21 and the
trimmed reads were subsequently aligned to the reference
genome (hg19, March 2009 assembly) using BWA mem version
0.7.12, allowing for a maximum of 5% mismatches in a read.
Single-nucleotide variation detection was performed using
SNPmania version 0.0.7 (Department of Immunology, Genetics
and Pathology, Uppsala University, Uppsala, Sweden) (Ljungström
et al, unpublished data, available on request) only considering
aligned reads with an alignment quality of at least 5 and read
bases with a minimum base quality of 20. These thresholds were
set based on optimal sequence concordance with HapMap variant
data. Insertion and deletion detection was performed using Pindel
version 0.2.5a8 with parameters -x 2, allowing the detection of
indels up to 512 bp, and -B 100 allowing the detection of
structural variants of size ~100 bp.
RESULTS
Establishment of patient-derived tumour cells (PDC) from sarcoma
patients
Soft tissue sarcomas were obtained by surgical excision, or by FNA
and were used to establish patient-derived sarcoma cell cultures,
hereby denoted as PDC. Normal healthy control cells were also
isolated and cultured from three healthy muscle biopsies, one
epithelial bladder biopsy, from umbilical cord-derived mesench-
ymal stem cells (commercial) and from the bone marrow of two
healthy donors. Representative samples from the biopsies were
dissected for (a) deep freezing, (b) formalin-fixed and paraffin
embedding (FFPE), (c) genotypic and transcription profiling and
(d) establishment of the PDC (Fig. 1). Fourteen primary cell
cultures could be grown in vitro from a total of 24 sarcoma
biopsies (58% recovery). The success in establishing the primary
cultures was dependent on the viability and size of the biopsy and
the treatment of the patient prior biopsy. The time from biopsy to
drug screening varied from 2 to 128 days, depending on these
conditions (Table 1). To investigate if the outgrowing PDC still
resemble the sarcoma tissues from which they were originated,
we determined the expression of fusion proteins in sarcomas with
translocations by proximity ligation assay (PLA) or RT-PCR. PDCs
originating from sarcomas with undefined genetic markers were
characterised by gene panel sequencing (Supplementary Table 1
and 2) and cancer-driver gene expression (Supplementary Figure 1
and Supplementary Table 4). The sarcoma subtypes and genetic
characteristics of the samples used in this study are presented in
Table 1.
Drug sensitivity and resistance testing (DSRT) on patient-derived
sarcoma cells (PDC)
The comparison of the DSS values among our sarcoma cohort (14
cases) showed that drug classes such as histone deacetylase
(HDAC), cyclin-dependent kinase (CDK), proteasome, mitosis, and
mTOR inhibitors were active in most of the sarcoma subtypes
tested. However, when normalising the DSS of the sarcoma PDCs
to that of healthy cells (bone marrow and mesenchymal controls),
to obtain the sDSS, we identified selective inhibitors such as
Dasatinib (Supplementary Figure 2).
We therefore correlated the drug responses for individual
sarcoma cases in relation to both healthy bone marrow and
healthy mesenchymal controls. In this stringent analysis, an sDSS
above 5 was considered a potential hit.
In the present study we show the functional and genotypic
analysis of six cases of patients affected with sarcomas with
translocations consisting of one aRMS, two alveolar soft part
sarcomas (ASPS), one synovial sarcoma (SS) and two Ewing
sarcoma (ES).
Case 1. Alveolar rhabdomyosarcoma (RMS1)
A 19-year-old male developed a primary tumour in the prostate
that was diagnosed as a PAX3-FOXO1-positive aRMS. He
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Fig. 1 Model of precision medicine for sarcoma patients. Illustration of our precision medicine model showing the process for the
establishment of patient-derived cells (PDC) from patient biopsies, the characterisation of the PDC by gene panel sequencing, cancer driver
gene expression and fusion oncoprotein expression in situ; and the drug sensitivity testing where active target inhibitors are identified for the
specific PDC. The results of the drug screens are reported back to the referring physicians in order to nominate a potential treatment for
refractory patients
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Scandinavian Sarcoma Group protocol III (ISG/SSGIII) consisting
of doxorubicin, vincristine and cisplatin (Supplementary Table 3).
The patient had a refractory and disseminated disease with
multiple metastasis in the lung, sacrum, arm and neck at the time
of biopsy. A sample from a palpable neck lesion was obtained by
FNA for drug screening ex vivo (Fig. 2a).
We detected the expression of the PAX3-FOXO1A fusion
transcript in the PDC (K-RMS1) by RT-PCR confirming the presence
of aRMS cells (Fig. 2b). Among the cancer driver genes expressed
in K-RMS-1 we found increments in the expression of BAX, RASD1,
WT1, AKT1, cMYC and NOTCH (Fig. 2c).
Figure 2d shows the selective drugs active in K-RMS1 that
included several kinase inhibitors such Crenolanib (Platelet-
Derived Growth Factor Receptor inhibitor); Dasatinib/Sprycel®
(cSrc inhibitor); Cabozantinib/Cabometix® (cMet and VEGFR
inhibitor); and Crizotinib/Xalkori® (targeting the Anaplastic Lym-
phoma Kinase ALK and cMET). Consistent with the patient
refractory disease, the drug screening test showed poor responses
for the drugs that the patient had received at the time of biopsy:
doxorubicin, cisplatin and vincristine (Fig. 2d, red dots) with sDSS
below 5. The patient died of progressive disease during the course
of the study.
Case 2. Alveolar soft part sarcoma
Two cases were investigated; one expressing the fusion protein
ASPS1-TFE3 (K-ASPS2) and a case where the fusion gene transcript
was not detected in either biopsy nor the PDC (K-ASPS3).
K-ASPS2 originated from the tumour of a 20-year-old female,
with a mass in the soleus muscle with a tumour morphology
characteristic of alveolar soft part sarcoma consisting of tumour
cells with eosinophilic cytoplasm and prominent nucleoli arranged
in small alveoli (Fig. 3a). Lung metastases were detected at
diagnosis. The fusion transcript ASPS1-TFE3 type 2 was detected in
the tumour biopsy at routine diagnosis. The tumour was surgically
removed, and the patient underwent oncological treatment with
adriamycin and ifosfamide (Supplementary Table 3), but devel-
oped multiple metastasis in the skeleton, mediastinum and
adrenal gland. A biopsy from a skeletal metastasis was then
obtained after palliative surgery for the establishment of the PDC
and the expression of the ASPS1-TFE3 fusion protein was
confirmed by PLA in 95% of the patient-derived sarcoma cells
(Fig. 3b).
At the time of biopsy, the patient had received treatment with
Sunitinib (Sutent®) Crizotinib (Xalkori®), Trabectedin (Yondelis®),
Denosumab (Xgeva®) and Pazopanib (Votrient®) with poor
responses and developed progressive disease (Supplementary
Table 3). Similarly, the drug sensitivity testing on the PDC showed
poor activity for all these drugs except for Pazopanib (Fig. 3c, red
dots).
Active drug classes were mTOR inhibitors and other multikinase
inhibitors such as Lucitanib and Tesevantinib. Interestingly, two C-
Met inhibitors, Golvatinib and MK2461, were identified as selective
hits (Fig. 3c, blue dots). The ASPS1-TFE3 fusion protein is a
transcriptional activator that directly targets and activates the
cMET promoter.22 The patient died of progressive disease during
the study.
The second ASPS case was a 22-year-old female with a 9 cm
primary tumour in the gastrocnemius muscle and lung metastasis
at diagnosis.
The primary tumour was surgically removed, and the diagnosis
confirmed morphologically as alveolar soft part sarcoma (Fig. 3a).
Fresh primary tumour was used for the establishment of the PDC
(K-ASPS3). The ASPS1-TFE3 was not detected by routine diagnosis
in the biopsy (data not shown) nor in the derived PDC; there the
PLA showed cytoplasmic but not nuclear ASPS1-TFE3 signals
(Fig. 3b).
Cancer driver gene expression was quantified in the ASPS3
biopsy and PDC. The apoptotic regulator (BAX), the
dexamethasone-induced Ras-related (RASD1), the Wilms Tumour
1 (WT1) and mTOR (FRAP1) kinase genes were among the most
Table 1. Origin and characteristics of patient-derived cells (PDC)
PDC Histological subtype Biopsy
method
Biopsy to PDC time
(days)
Genetic marker
Sarcoma with translocations K-RMS1 Alveolar rhabdomyosarcoma FNA 44 PAX3-FOXO1
K-ASPS2 Alveolar soft part sarcoma S 31 ASPSCR1-TFE3
K-ASPS3 Alveolar soft part sarcoma S 9 TP53 mutation (p.R205H)
K-ES1 Ewing sarcoma FNA 110 EWSR1-FLI
K-ES2 Ewing sarcoma FNA 49 EWSR1-FLI1
K-SS3 Synovial sarcoma FNA 49 SS18-SSX
K-SS2 Synovial sarcoma S 128 SS18-SSX not detected
Sarcomas with complex
genomes
K- MPNST1 Malignant peripheral nerve sheath
tumour
S 19 TP53 mutation (p.R150W)
K-MPNST2 Malignant peripheral nerve sheath
tumour
S 47 Not analysed
K-MPNST3 Malignant peripheral nerve sheath
tumour
S 30 No mutations found
K-AS1 Angiosarcoma FNA 45 No mutations found
K-UPS1 Undifferentiated pleomorphic sarcoma S 32 No mutations found
K-MFS1 Myxoid fibrosarcoma S 2 TP53 (p.P146S);BRAF
(p.Q257H)
K-LMS1 Leiomyosarcoma FNA 77 PI4KA (p.R906H)
Healthy controls K MC-1 Normal muscle S 23 Not analysed
K MC-2 Normal muscle S 18 Not analysed
K MC-3 Normal muscle S 19 Not analysed
K MC-4 Mesenchymal stem cells (commercial) UC 2 Not analysed
K MC-5 Normal bladder fibroblasts S 20 Not analysed
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Fig. 2 Alveolar rhabdomyosarcoma patient-derived cells (K-RMS1). a Giemsa staining of the fine needle aspiration biopsy (FNA) showing high
content of rhabdomyosarcoma cells and a light microscopy picture (×10) of the derived PDC. b RT-PCR showing the expression of PAX3-
FOXO1A in the PDC (K-RMS-1) after 2 and 8 weeks of in vitro culturing. RH30 is an alveolar rhabdomyosarcoma cell line used as a positive
control. Primary muscle cells were used as negative control. c Heatmap illustrating cancer driver genes expressed in K-RMS-1 at the time of
drug screening. Relative expression (normalised to muscle cells) is expressed as log2 fold change. Values were calculated using the Livak
method. d Plot showing the selective drug sensitivity scores (sDSS) of K-RMS1 in relation to normal bone marrow mononuclear cells (Y-axis),
and healthy mesenchymal cell controls (X-axis). The patient treatment at the time of biopsy is highlighted in red
























































































































































Fig. 3 Alveolar soft part sarcoma patient-derived cells (K-ASPS2 and K-ASPS3). a Haematoxylin and eosin staining of formalin-fixed ASPS
biopsies and the derived PDC (visualised by light microscopy). b Proximity ligation assay showing nuclear expression of the ASPS1-TFE3 fusion
protein in the K-ASPS2 cells and cytoplasmic signals in K-ASPS3. Muscle cells as negative control. c Expression of cancer driver genes
determined by Q-RT-PCRT in the K-ASPS3 relative to normal muscle cells. d Plot showing the drug activity in K-ASPS2 and e K-ASPS3
respectively. Patient treatment at the time of biopsy is highlighted in red
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expressed genes in relation to normal muscle cells (Fig. 3d and
supplemental Fig. 1)
Consistent with the activation of mTOR/PI3K pathway in the
ASPS3 biopsy and derived PDC, several mTOR/PI3K inhibitors were
active in functional screens such as PF04691502, Dactolisib and
Gedatolisib with sDSS values above 10 in relation to healthy bone
marrow cell controls. Other selective hits for K-ASPS3 were the
purine analogue Fludarabine, the folate anti-metabolite Peme-
trexed, the cell division cycle 7 homologue (CDC7) kinase inhibitor
BMS-863233, and the topoisomerase inhibitor Topotecan. Similar
to K-ASPS2 and K-RMS1, Dasatinib was an active drug in K-ASPS3
(Fig. 3e, green dot).
This patient was treated with Sunitinib™, developed progressive
disease with brain metastasis that was treated with whole brain
radiation 4GyX5; and later developed lung metastases and was
treated with doxorubicin. The patient has progressive disease at
present, with new cerebellar lesions, underwent surgery and is
now on treatment with Dasatinib.
Case 3. Synovial sarcoma
A 33-year-old female presented with a 9.9 × 7 cm tumour in the
gastrocnemius. The tumour consisted of spindle cells positive for
TLE1 and CD99 and for the fusion transcript SS18-SSX determined
in routine diagnosis. A piece of the tumour and of healthy muscle
were obtained for the establishment of sarcoma and muscle PDC
(Fig. 4a). The synovial sarcoma biopsy and derived PDC (K-SS3) but
not the muscle biopsy or the cultured muscle cells expressed the
SS18/SXX fusion as determined by RT-PCR (Fig. 4b). However,
approximately 40% of the cells in K-SS3 expressed the SS18/SSX-
TLE1 fusion protein complex as determined by PLA (Fig. 4c).
Among the genes expressed in the K-SS3 biopsy and PDC were
WT1, BAX, N-MYC, HIF1α, SOX9, and autophagy-related genes
(Fig. 4d).
Few inhibitors were selectively active in K-SS3 such as the PI3K
inhibitor Copanlisib/Aliqopa™, the ALK/FAK1 inhibitor CEP-37440,
the MEK inhibitor AZD-8330 and the AKT inhibitor Triciribine
(Fig. 4e). Consistent with previous reports demonstrating the
activity of HDAC inhibitors in synovial sarcomas, several HDAC
inhibitors had significant activity in this PDC when normalised
with normal mesenchymal controls (Fig. 4e, green dots and
supplementary Figure 2); however, they showed toxicity for the
bone marrow cell controls (low sDSS bone marrow controls).
Several mTOR/P13K (Fig. 4e, turquoise dots) and the cSrc inhibitor
Dasatinib (Fig. 4e, green dot) showed anti-tumour activity in K-SS3.
At present, the patient has no evidence of disease.
Case 4. Ewing sarcoma
Two Ewing sarcomas PDC were established from FNA biopsies of
two patients: K-ES1 and K-ES2.
K-ES1 was obtained from an FNA of a primary tumour in the
right scapula of a 26-year-old male, prior to oncologic treatment
(Fig. 5a). The EWSR1-FLI1 fusion was detected in the biopsy (data
not shown) and in 95% of the cells in the PDC confirming the
presence of Ewing sarcoma cells (Fig. 5b). Cancer driver gene
expression was characterised by the expression of the DNA
damage inducible transcript 3 (DDIT3), the mTOR kinase gene
FRAP1, the anti-apoptotic gene BCL2 and several autophagy-
related genes of the ATG and SEC family, and downregulation of
the TP53 gene among others (Fig. 5c).
The patient presented with bone marrow, skeleton and lung
metastases at diagnosis and was treated with Scandinavian
Sarcoma Group protocol IV (SSGIV) protocol consisting of cisplatin,
doxorubicin, etoposide and vincristine with no clinical response
(Supplementary Table 3). Consistent with the patient clinical
response to treatment, no activity for these drugs was observed in
the drug screening assay (Fig. 5d, red dots). However, several
selective inhibitors were identified for this patient tumour
cells such as cSrc inhibitors Dasatinib and Saracatinib (Fig. 5d,
green dots), the FGF inhibitor LY-2874455, the PAK inhibitor
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Fig. 4 Synovial sarcoma patient-derived cells (K-SS3). a Haematoxylin and eosin staining showing spindle-like cells, characteristic of synovial
sarcoma. The derived PDC (K-SS3) is visualised by light microscopy. b RT-PCR showing the expression of SS18-SSX in the biopsy, PDC and in
control Syo1 cells. c Proximity ligation assay showing the expression of the SS18-SSX/Tle fusion protein complex in 40% (yellow) of K-SS3 cells
and in the synovial sarcoma cell line Syo-1. d Heatmap comparing cancer driver gene expression in the synovial sarcoma biopsy and derived
PDC. e Plot showing the selective drug sensitivity scores (sDSS) in relation to normal bone marrow mononuclear cells (Y-axis) and healthy
mesenchymal cell controls (X-axis)
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patient developed systemic disease and died few months after
diagnosis.
K-ES2 originated from a 31-year-old male diagnosed of Ewing
sarcoma. The patient received adjuvant treatment with vincristine,
doxorubicin and cyclophosphamide (SSGIV) and radiotherapy (1,8
GyX28), followed by autologous stem cell transplantation (Sup-
plementary Table 3). Thereafter, the patient underwent surgery
with complete resection of the primary tumour. After a 3-year
disease-free survival the patient developed metastasis in the third
right rib. An FNA biopsy was taken from this lesion and the
tumour cells were cultured in vitro (K-ES2). The EWS-FLI1 fusion
protein specific for Ewing’s sarcoma was expressed in 95% of the
cells in the PDC culture (Fig. 5b). The patient metastasis was
treated with docetaxel and gemcitabine before surgery according
to the SSGIV protocol and achieved complete response (Fig. 5e).
Consistent with the clinical response of the patient, the ex vivo
drug sensitivity testing of his tumour cells (K-ES2) showed activity
for the taxanes docetaxel, paclitaxel and cabazitaxel (Fig. 5d), but
not for gemcitabine suggesting that the complete clinical
response could be attributed to the taxane treatment.
The cSarc and ALK inhibitor Dasatinib is active in several sarcoma
subtypes
Dasatinib/Sprycel is a tyrosine kinase inhibitor that blocks the
activity of several tyrosine kinases including Bcr-Abl and members
of the Src kinase family. Dasatinib was active in all PDCs derived
from sarcomas with translocations and other sarcoma subtypes
(Figs. 2−5 and Supplementary Figure 2).
DISCUSSION
Phenotypic screening for anticancer drugs has long relied on
cytotoxic assays using cancer cell lines, spheroids and xenografts.
Although these models have been used extensively for cancer
drug development, they have important limitations since serially
passaged cell lines lose the genetic characteristics of the primary
tumours of origin. Genomic sequencing of cancer cell lines has
shown that mutations accumulate during serial passages.10,11
Gene expression is even more affected in cultured cell lines,
likely as the result of selection pressure that allows the cells to
survive under in vitro conditions. Genes associated with multidrug
resistance or with the p53 pathway are reactivated upon in vitro
cell culturing.23 We observed an overexpression of genes
associated with autophagy and vesicle formation in the PDCs
but not in the biopsy of origin, indicating that in vitro culturing of
primary cells activates functions associated with degradation,
transport and recycling of cellular components.
Experimental cancer models have been developed for func-
tional screens such as patient-derived tumour xenografts (PDX),
ex vivo culturing of tissue slices,24 and the use of low passaged
PDC. All these models are better surrogates of the tumours from
which they were generated and are being used in precision
medicine in which the genomic and functional signatures of
patient tumours are used to find rational treatments for individual
patients.
Sarcoma is a highly heterogeneous and aggressive disease in
which some histological subgroups lack efficient treatments.
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Fig. 5 Ewing’s sarcoma patient-derived cells K-ES1 and K-ES2. a Giemsa-stained fine needle aspiration (FNA) biopsy and PDC (K-ES1) visualised
by light microscopy. b Proximity ligation assay showing the expression of the EWS1-FLI1 fusion protein in K-ES1 and K-ES2 and in the Ewing’s
sarcoma cell line SK-ES. c Cancer driver gene expression in K-ES1. d Drug activity in K-ES1 and f K-ES2 expressed as selective drug sensitivity
scores (sDSS). e CT scans showing a rib metastasis of ES1 patient donor (yellow circles) before and after taxane treatment
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Gleevec® for the treatment of gastrointestinal stromal tumours,
other specific targets have been identified for sarcomas such as
PDGFRα and β, c-Met, PI3K-AKT, HDAC, MDM2 and IGF1R, and
inhibitors targeting these pathways have been developed and
evaluated in preclinical and clinical trials.25,26
In this study, we cultured and characterised patient-derived
sarcoma cells to test their sensitivity towards a comprehensive
library of cancer drugs as an approach to identify selective
inhibitors for individual cases. Twenty-four sarcoma biopsies were
taken but only 14 of them could be grown in vitro. Most of the
biopsy donors were affected by progressive disease and had been
treated with systemic chemotherapy or radiation at the time of
biopsy. Although it is difficult to draw conclusions from a small
cohort we observed that poor cell viability in the sample, and
adjuvant treatment prior to biopsy, had negative effects on the
establishment of PDCs.
Several sarcoma groups are already using functional screens to
identify targeted inhibitors for sarcoma. In a recent study, 63
human adult and paediatric sarcoma cell lines were screened
against 445 cancer agents including 100 approved drugs. The cell
panel consisted of 15 sarcoma subtypes with an overrepresenta-
tion of osteosarcoma and Ewing sarcoma cell lines. The drug
response results showed that sarcomas are in general poor
responders. Ewing sarcoma however was the most responsive
group in this series. The drug responses varied within the groups
and was associated with specific gene or microRNA expression.
Normal healthy controls were not assessed, and several cell lines
used in this study have been cultured in vitro for several years.27
Two recent studies have shown that patient-derived tumour
xenografts (PDX) and low passaged s PDCs preserve the intra-
tumour heterogeneity and the genomic fingerprint of the tumours
of origin.14,15 In this study, whole exome sequencing was
performed in a large panel of tumours and demonstrated that
patients with advanced cancers carry limited number of targetable
genomic aberrations. Similar to our results they show that in vitro
drug testing on patient-derived cells can potentially predict
patient response to therapy, and it is advantageous when
genomic profiling fails to identify targetable genomic alterations.
The power of using patient-derived sarcoma cells to predict
patient response to drug treatment has not been evaluated in big
cohorts. Recently, patient tumours engrafted in mice were used as
a predictive model for response to therapy. In this study, 29
human sarcomas were transplanted in immunodeficient mice
(TumorGraft) and 22 (76%) of them engrafted and were
subsequently passed in mice for drug sensitivity testing. The
most relevant finding was that TumorGrafts could predict
response to treatment in 13 of 16 cases of sarcoma patients
undergoing treatment; however, time from tumour engraftment
to drug sensitivity assay was several months,28 and this represents
a limitation if the patient has progressive disease. These results
however demonstrate that patient-derived sarcoma cells or
xenografts are relevant models that can be used to identify
effective treatments for sarcoma patients.
In our study we found several indications that support the use
of sarcoma PDC in drug screens as a predictive model of patient
treatment response. First, we could confirm that the genetic
characteristics of the sarcoma biopsies such as gene mutations
and fusion gene expression were preserved in early passaged
PDCs. Secondly, there was an association between drug sensitivity
and the response to the patient’s actual treatment. Poor DSS in
drugs used in routine treatment were observed in patients with
refractory disease, contrary to a case of a taxane responsive Ewing
sarcoma in which taxanes showed activity in vitro.
Thirdly, c-Met inhibitors were active in an ASPS1-TFE3-positive
alveolar soft part sarcoma consistent with the targeting of the
cMET promoter by ASPS1-TFE3.
It is also possible that the lack of response of cultured sarcoma
cells from patients with recurrent disease is the result of the clonal
evolution of their tumour clones resistant to treatment that are
preserved in the PDC. The comparison of drug responses between
primary and metastatic tumours could shed information and is an
issue of interest for further investigations.
In summary, our pilot study shows that patient-derived sarcoma
cells can be isolated from surgical and FNA biopsies and expanded
in vitro to be used in comprehensive drug sensitivity testing. This
is a rapid approach that does not require animal facilities or the
reprogramming of cells to establish the PDCs. It can identify
selective agents with activity in sarcomas from individual patients
and can predict the patient response to standard-of-care
treatment. This method can be used as a guide to select
treatments for sarcoma patients with otherwise few therapeutic
options; however, trials with larger cohorts need to be performed
to confirm its clinical value.
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